Merck's Mavenclad tab. (cladribine), which is used to treat relapsing-remitting multiple sclerosis, has become subject to price cuts under the price-volume agreement and will be sold at a 6.9% lower price starting next month.

The price of Boryung’s flagship hypertension drug, Kanarb (fimasartan potassium trihydrate), will be reduced by 1.7% for each dose, and the price of BMS Korea Eliquis will also be reduced by 3.5% for each dose.

According to industry sources on the 21st, the Ministry of Health and Welfare is planning to revise the 'Drug Reimbursement List and Reimbursement Ceiling Amount Table' and apply it on the 1st of next month.

A total of 6 products will be applied P